Uveal Melanoma

P1, N=75, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

Three-dimensional culture architecture was associated with differential modulation of stemness- and epithelial-to-mesenchymal transition-associated transcription in uveal melanoma. Platform selection and tumour origin were associated with differences in the phenotype observed in vitro and should be carefully aligned with specific biological endpoints when modelling disease progression.

Vision improved following four sessions of proton beam therapy. This case highlights the importance of multidisciplinary involvement, multimodal imaging, and gene expression profiling in facilitating early diagnosis and treatment.

These data provide new insights into Gαq-driven modulators of UM phenotype of relevance for studies of tumor-microenvironment interaction and metastasis.

Single-cell transcriptomic analyses further resolved cell-type-specific expression patterns, distinguishing tumor-intrinsic from immune-restricted expression profiles. Collectively, our findings establish CD70, CD80, and TIGIT as integrative biomarkers of tumor progression, immune contexture, and therapeutic response, providing a rationale for their clinical exploitation in precision immuno-oncology.

P2, N=12, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | N=37 --> 12 | Trial primary completion date: Dec 2026 --> Jul 2026 | Recruiting --> Active, not recruiting

ADI-PEG20 downregulated multiple genes of the Fanconi anemia pathway and synergized with melphalan to increase DNA double-strand breaks. Melphalan and pegargiminase is a rational new drug combination that warrants clinical testing in uveal melanoma.

A significant negative correlation between RiskScore and the IC50 of XMD8-85, lapatinib, roscovitine, salubrinal, bexarotene, LFM-A13, FTI-277, and TGX221 chemotherapeutic agents was further noticed. In this study, we computationally identified genes associated with both disease progression and macrophage/monocyte-related characteristics in UVM and constructed a prognostic risk model with predicted immune infiltration patterns. These findings generate testable hypotheses that may inform future experimental studies on the immune mechanisms underlying UVM.

Ipilimumab combined with nivolumab has demonstrated superior outcomes, earning a median overall survival surpassing 70 months...The advent of new ICIs, such as relatlimab, introduces additional complexities in decision-making for first-line therapy...The FDA approval of tebentafusp and lifileucel has demonstrated potential in extending the survival time of patients with metastatic uveal melanoma...It aims to facilitate informed treatment decisions and enhance understanding of the multifaceted challenges in effectively managing advanced melanoma. As new therapies emerge, continuous education and adaptability will be key to optimising patient outcomes.

Notably, early 6p gain was frequently exclusive of BAP1 aberrations and associated with a favourable prognosis, suggesting that metastatic potential in UM may be established early during tumorigenesis. Collectively, our findings provide molecular changes contributing to tumorigenesis and metastatic progression in UM and offer potential biomarkers for early detection and prognosis prediction.

This meta-analysis offers new insights into the genetic architecture of UM, highlights potential therapeutic targets, and explores the genetic relationship with CM and skin pigmentation.

This case illustrates a rare late local recurrence of choroidal melanoma with different appearance from the original tumor. It also highlights the diagnostic and prognostic role of transretinal biopsy in confirming the nature of the lesion as a recurrence and the option of proton beam radiation as salvage therapy.